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Virulence, drug sensitivity and transmission
success in the rodent malaria,
Plasmodium chabaudi
Petra Schneider1,2,3,*, Andrew S. Bell4,5, Derek G. Sim4,5,
Aidan J. O’Donnell2,3, Simon Blanford4,5, Krijn P. Paaijmans4,5,
Andrew F. Read4,5,6 and Sarah E. Reece1,2,3
1Centre for Immunity, Infection and Evolution, 2Institute of Evolution, and 3Institute of Immunology and
Infection Research, School of Biological Sciences, University of Edinburgh, Edinburgh EH9 3JT, UK
4Department of Biology, and 5Department of Entomology, Center for Infectious Disease Dynamics,
Pennsylvania State University, University Park, Pennsylvania 16827, USA
6Fogarty International Center, National Institutes of Health, Bethesda, MD 20892, USA
Here, we test the hypothesis that virulent malaria parasites are less susceptible to drug treatment than less
virulent parasites. If true, drug treatment might promote the evolution of more virulent parasites (defined
here as those doing more harm to hosts). Drug-resistance mechanisms that protect parasites through
interactions with drug molecules at the sub-cellular level are well known. However, parasite phenotypes
associated with virulence might also help parasites survive in the presence of drugs. For example, rapidly
replicating parasites might be better able to recover in the host if drug treatment fails to eliminate para-
sites. We quantified the effects of drug treatment on the in-host survival and between-host transmission of
rodent malaria (Plasmodium chabaudi) parasites which differed in virulence and had never been previously
exposed to drugs. In all our treatment regimens and in single- and mixed-genotype infections, virulent
parasites were less sensitive to pyrimethamine and artemisinin, the two antimalarial drugs we tested.
Virulent parasites also achieved disproportionately greater transmission when exposed to pyrimethamine.
Overall, our data suggest that drug treatment can select for more virulent parasites. Drugs targeting
transmission stages (such as artemisinin) may minimize the evolutionary advantage of virulence in
drug-treated infections.
Keywords: competition; drug resistance; fitness; genetically diverse infection; transmission;
virulence evolution
1. INTRODUCTION
Radical alterations in parasite ecology such as that
imposed by drug treatment can exert selective effects on
the life-history traits and behaviours of parasites [1–5].
For example, traits that govern the growth and reproduc-
tive patterns of parasites can influence their survival and
transmission in drug-treated infections [6–18]. These
life-history traits need not involve direct intracellular
interactions with drug molecules, yet can reduce sensi-
tivity to treatment. They are therefore drug-resistance
traits in the broadest definition. We call life-history
phenotypes which confer reduced susceptibility ‘non-
classical resistance’ to make a clear distinction from the
traditionally studied mechanisms of drug resistance
(classical resistance). Non-classical resistance traits are
diverse. They include bacterial biofilms that act as drug
barriers [16,17], the formation of latent stages, such as
bacterial persister cells and quiescent stages in malaria
parasites that survive drugs through reduced metabolic
activity during exposure [9–11,18], and faster replication
rates in malaria parasites and worms that may provide
protection through safety in numbers or by minimizing
the period when a vulnerable life-cycle stage is exposed
to drugs [12,15]. Importantly, these life-history traits
can also underpin both virulence and transmission
[12,19–21]. We define virulence as the harm caused by
parasites to their hosts. If virulence-related traits reduce
drug sensitivity, drug treatment which does not clear all
parasites might confer a selective advantage on more viru-
lent parasites. This could lead to the spread of more
virulent parasites in a population. This evolution would
have consequences for public and animal health: not
only would drug efficacy be eroded, hosts would be at
greater risk of acquiring parasites that caused more
severe disease.
In an earlier study with the rodent malaria Plasmodium
chabaudi, we found that more virulent parasites had a
survival advantage in infections treated with the anti-
malarial drug pyrimethamine [12]. In those studies, we
tested virulent and avirulent genotypes from the same
genetic background which had never been under drug
selection. Specifically, we treated single-genotype infec-
tions with pyrimethamine that kills the asexually
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replicating stages (the stages responsible for disease symp-
toms). Here, we examine whether the survival advantage
of the virulent parasites also occurs in a wider range of
conditions and whether it results in increased transmis-
sion. Both in-host survival and transmission to vectors
are key components of fitness for malaria parasites and
so need to be examined to determine whether drug
treatment could generate population-wide evolutionary
change to virulence. We present a series of experiments
asking the following questions: does virulence reduce sen-
sitivity to different treatment regimens of artemisinin, an
antimalarial drug which kills transmission stages as well as
asexual stages [22] and is currently the frontline drug of
choice in much of the world [23]? Does the survival
advantage hold when parasites are competing in geneti-
cally diverse infections? What are the transmission
consequences of virulence in pyrimethamine- and in arte-
misinin-treated infections? Our data reveal that virulence
enhances in-host survival in single and mixed infections
treated with either pyrimethamine or artemisinin, and
when exposed to drugs, host-to-vector transmission is
also enhanced for virulent parasites, an advantage that is
minimized by treatment with artemisinin. Overall, our
data are consistent with the hypothesis that drug treatment
can select for the evolution of virulence.
2. MATERIAL AND METHODS
(a) Parasites, hosts and drugs
Hosts were 6–10-week-old C57Bl/6J female mice, with
access to food and drinking water supplemented with 0.05
per cent para-amino benzoic acid [24] ad libitum. The orig-
inal P. chabaudi isolates were obtained from thicket rats from
the Central African Republic (CW) and the Republic of
Congo (DK) [25]. Genotype P. chabaudi chabaudi CWavir
(CW175 lineage) was obtained after cloning of the wild isolate
and four passages in mice. CWvir (CW202 lineage) was
derived from CWavir by 11 serial passages in mice [26,27].
Serial passage of short-term infections between naive hosts
results in increased virulence [28]. The virulence phenotypes
of both CW genotypes are stable through freeze–thaw cycles,
suggesting that their traits are based on epigenetic inheri-
tance or fixed mutations. Plasmodium chabaudi adami
genotype DK25p was used as a reference genotype, which
was obtained from the original isolate after mosquito passage
and cloning. DK was used as a reference genotype because:
(i) all DK parasite stages can be distinguished from all
CW parasite stages by quantitative PCR assays; (ii) it is sen-
sitive to the drugs used in our experiments and its intrinsic
drug sensitivity is the same in mixed-genotype infections
with CWvir or CWavir; and (iii) its virulence level and com-
petitive ability are intermediate between CWavir and CWvir
(see the electronic supplementary materials, data S1 and
figure S1). None of the parasite genotypes used, or any of
their ancestors, had been exposed to antimalarial drugs
prior to these experiments. All mice were infected with 105
parasites of either CWavir or CWvir and mice in the compe-
tition experiments (experiments 3 and 4) also received 105
parasites of the reference genotype DK. Artemisinin (exper-
iments 1–4) and pyrimethamine (experiment 4) were
dissolved in dimethyl sulphoxide at the required concen-
tration and injected intraperitoneally with a maximum total
volume of 50 ml.
(b) Experiments 1–3: in-host replication
In our first 3 experiments, we tested whether virulence pro-
vides an in-host survival advantage (density of asexually
replicating stages) to parasites exposed to artemisinin treat-
ment. We varied key components of drug treatment regimen
(dose and duration): artemisinin treatment lasted for 4 days
in experiment 1 and 1 day in experiment 2, and the doses
used span from placebo to the maximum non-toxic dose for
the duration of treatment as determined from pilot exper-
iments. The drugs, doses and numbers of independent
infections for each treatment group, in each experiment, are
given in table 1. We tested whether virulence provides in-
host survival advantages to parasites in single-genotype
infections in experiments 1 and 2; and in experiment 3, we
examined parasites in the more ecologically realistic scenario
of genetically diverse infections. Because the avirulent and
virulent CWgenotypes cannot be distinguished bymicroscopy
or molecular methods, we competed both CWvir and CWavir
against a commongenotype,DK, using the same treatment regi-
mens (dose and duration of treatment) as for experiment 2.
We monitored all infections throughout the acute phase
(days 3–21) with daily measurements of red blood cell
(RBC) loss, weight loss and daily collection of samples for
parasite and gametocyte quantification by microscopy
and/or molecular methods.
Table 1. Drugs, doses and number of independent infections for all experiments. Each asterisk (*) indicates a mouse
euthanized early (days 9–12) in the experiment because of severe anaemia and excluded from analysis of in-host survival.
no competition competition
experiment 1 experiment 2 experiment 3 experiment 4
4 day duration 1 day duration 1 day duration 1 day duration
dosea CWavir CWvir CWavir CWvir CWavir CWvir CWavir CWvir
placebo 5* 8*** 5 7** 5 5* 4 4
ART 50 5 5 5 5 5 5 4 4
ART 100 5 5 5** 5 5 5 4 4
ART 150 5 5 — — — — — —
ART 200 — — 5 5* — — — —
PYR 1 — — — — — — 4 4
PYR 3 — — — — — — 4 4
aDose: dose of artemisinin (ART) or pyrimethamine (PYR) in mg kg mouse21 day21, starting from day 5 after infection.
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For experiments 1 and 2, asexual parasites were counted
by microscopy. Microscopy counts were obtained from the
number of parasitized RBC observed per 1000 RBC on
Giemsa-stained thin smears, made from tail bleeds, and we
used RBC density determined by flow cytometry to calculate
parasite density per millilitre of blood. In experiment 3,
asexual parasite densities for CWvir or CWavir and DK were
calculated by subtracting the number of gametocytes from
the total number of parasites detected by quantification of
cDNA or DNA of the gametocyte-specific expressed gene
PC302249.00.0 by genotype-specific PCR. As we are inter-
ested in the effects of drugs over the entire duration of the
infections, we used cumulative CWvir or CWavir asexual para-
site densities from the time of drug treatment to the end of
the infection to investigate in-host survival and the effects
of drug treatment in both single- and mixed-genotype infec-
tions. Cumulative densities of reference genotype DK were
analysed to verify that in-host competition occurred (see the
electronic supplementary material, data S1 and figure S1).
(c) Experiment 4: between-host transmission
To examine the transmission consequences of drug treatment,
we infected 40micewith the reference genotypeDKand either
CWavir or CWvir as per experiment 3. These mice were treated
with either placebo, a single dose of 50 or 100 mg kg21 artemi-
sinin, or with a single dose of 1 or 3 mg kg21 pyrimethamine,
a drug for which we have already demonstrated the in-host
survival benefits of virulence [12] (table 1).
Cages of laboratory-reared Anopheles stephensi mosquitoes
(n ¼ 50) were starved overnight and allowed to feed on two
anaesthetized mice (1 cage per mouse) per treatment group
at day 7 post infection (one gametocyte development cycle
after drug treatment) and again on days 11, 15 and 19
(n ¼ 80 cages with 50 mosquitoes each) to estimate overall
(cumulative) transmission success for parasites in each treat-
ment group. Unfed mosquitoes were removed, and fed
mosquitoes were kept for 7–8 days to allow fertilized para-
sites to develop into oocysts and produce sporozoites (the
stages infective to new hosts). For each feed, 25 mosquitoes
were dissected to determine the percentage of infected
mosquitoes (n ¼ 2000 mosquitoes). We quantified the
number of genomes of CWavir or CWvir and DK for up to
six infected mosquitoes per feed (n ¼ 188 mosquitoes, from
40 feeds that resulted in infected mosquitoes) using the
genotype-specific PCR assays used in experiment 3 to calcu-
late the proportional representation of the CWavir or CWvir
and DK alleles as a measure of relative fitness of the different
genotypes. Two of the 80 feeds were excluded, one because
the mouse was not infected and one because only five
mosquitoes survived. Samples from all infected mice were
collected on day 5, before drug treatment and on days 7,
11, 15 and 19 to verify that the dynamics of asexual and
gametocyte densities were comparable in experiments 3
and 4 (see the electronic supplementary materials, data S1).
(d) Genotype-specific quantification of parasites
For DNA extraction, RBC pellets of 5 ml blood samples, col-
lected in citrate saline, were stored at 2808C. DNA
extraction was performed using the ABI Prism 6100 and
BloodPrep Kit (Applied Biosystems, Foster City, USA)
according to the manufacturer’s protocol [29]. For RNA
extraction, 10 ml blood samples were added to 30 ml nucleic
acid purification lysis solution (Applied Biosystems) and
15 ml PBS, gently mixed and stored at 2808C. RNA was
extracted using the ABI Prism 6100, and cDNA was
obtained by reverse transcriptase PCR (high-capacity
cDNA archive kit, Applied Biosystems) according to the
manufacturer’s protocols [30]. For experiments 3 and 4,
total parasites and gametocytes were counted using quanti-
tative real-time PCR, using, respectively, DNA and cDNA
and primers and probe based on the gametocyte-specific
expressed gene PC302249.00.0. The assay was designed to
distinguish parasites and gametocytes of reference genotype
DK from CW, using primers DKcg2F: 50-GGATGACTT-
TAGATATTTAATAAATGAT TTAGAATTC-30, DKcg3R:
50-CTACTTTGAATTCATC TAAATGATTTGATTTT-30
and probe DKcg2: 50-FAM-CCAAGAGATAAA-
GAAAAGGTATT-MGB-30. For direct comparison of
quantification in samples from mixed-genotype infections
using the same probe DKcg2, the qPCR assay that is able to
distinguish CW from DK (described as specific for the detec-
tion of P. chabaudi genotype AS in Drew & Reece [29]) was re-
designed to target the same region of the gene as the new DK-
specific assay. The primers used are CWcg2F: 50-GGAT-
GACTTTAGATATTTAAT AAATGATTTAGAATTT-30
and CWcg3R: 50-CTACTTT GAATTCATCTAAAT-
GATTTGATTTC-30. For these assays, primers were used at
a concentration of 900 nM and probes at 125 nM. The per-
formance of the qPCR was validated using microscopy-
derived parasites counts. Dilution series of positive control
samples, initiated frommice infected with P. chabaudi of geno-
type CW or DK, were tested in concentrations ranging from
0.022 to 1.0 104 gametocytes ml21 and 5640 to 1.5  106
parasites ml21 to enable quantification of, respectively, game-
tocytes and total parasites in experimental samples. The
newly designed qPCR assays for CWand DK were confirmed
to be genotype-specific and quantification was robust also in
the presence of a range of DNA concentrations equivalent to
102–105 parasites of the non-target genotype. Both the CW-
and DK-specific PCRs had a lower detection limit of at least
150 parasites and 10 gametocytes per microlitre of blood,
and parasite and gametocyte numbers have a high correlation
to threshold cycle (Ct) values from the PCR (r2 ¼ 0.98, p,
0.001 for total parasites and r2 ¼ 0.93, p, 0.001 for gameto-
cytes; electronic supplementary material, figure S2).
(e) Classical drug-resistance genotyping
Reduced sensitivity to artemisinin and its derivatives has been
documented in various species of malaria parasites [31–35].
Single nucleotide polymorphisms in the ubiquitin-specific
protease-1 gene (ubp1) have been repeatedly associated with
lower sensitivity to artemisinins in P. chabaudi. Therefore, we
tested CWavir, CWvir, and all samples that contained parasites
at the end of our experiments for reported mutations in
ubp-1 to examine whether ‘classical’ resistance arose during
any experiments. Forward primer Pcpf01-0197-07: 50-AT
GCAAACTTACTTTCAAAACG-30 and reverse primer
Pcpf01-0197-04: 50-TTGTTGCATTTCGAGCATTTG-30
were used to amplify the region of the ubp-1 gene that contains
possible mutations involved in artemisinin resistance [31,36].
PCR products were purified and sequenced in both forward
and reverse direction using primers: Pcpf01-0197-08:
50-CAAATAAAAAATATGTTTCACCAG-30, and Pcpf01-
0197-R1: 50-CGAGCATTTGTATTTATTGTTTCC-30 to
detect presence of reported artemisinin resistance mutations
in ubp-1 [31]. None of the reported artemisinin resistance
mutations were detected before or after artemisinin treatment
in any of the experiments.
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(f) Statistical analyses
Analyses were performed in R v. 2.11.1 (The R Foundation
for Statistical Computing, Vienna, Austria). Models were
minimized using step-wise deletion of the least significant
term, and only significant effects are reported. To test the
in-host survival of CWvir compared with CWavir parasites
exposed to drug treatment (experiments 1–3), we used gen-
eralized linear models (GLM) with CW-specific cumulative
asexual parasite counts (days 6–21 of infection) after 10log-
transformation to meet assumptions of normality and
homogeneity of variance. Full models included the main
effects of virulence classification (genotype, CWavir or
CWvir), drug dose, experiment number (which controls for
the effects of both longer duration of treatment in experiment
2 and of competition in experiment 3) and all two and three-
way interactions. To control for baseline variation between
individual mice we fitted covariates for weight and RBC
density at the day of infection, and CW asexual parasite
density at the start of treatment was fitted to control for poss-
ible differences in numbers of parasites present at the time
of treatment.
Tocompare the transmission success ofCWvir comparedwith
CWavir parasites exposed to drug treatment (experiment 4),
we undertook several analyses. First, we tested whether the
virulence classification of the CW genotype in mixed infec-
tions and drug treatment determined the probability of
infecting mosquitoes, and whether drug treatment dispropor-
tionally affected mosquito infection by either the CWvir or
CWavir genotype (genotype–by-dose interaction). Because
mosquito infection data are highly overdispersed, we used
generalized linear mixed models using Markov Chain
Monte Carlo techniques (MCMCglmm [37]; electronic sup-
plementary material, data S2), which includes an
observation-level random effect that deals with any overdis-
persion in the data. We fitted a binomial error structure
and mouse was included as a random effect to adjust for
non-independence associated with repeated sampling of
each infection. Models included the main effects of virulence
classification (genotype CWavir or CWvir), drug dose and
their interaction. Because it is expected that the percentage
of infected mosquitoes increases with the number of gameto-
cytes present in the bloodmeal [38], we also fitted 10log
transformed total (CW þDK) gametocyte density at the
time of mosquito feeds as a covariate. Second, we tested
whether the fitness of CW (the proportional representa-
tion of CW compared with DK alleles) within infected
mosquitoes was influenced by virulence classification, drug
treatment and their interaction. Proportions of CW alleles
were arcsine square root transformed and used as a response
variable in generalized linear mixed models with the same
main effects fitted as for the analysis of the proportion of
mosquitoes infected and the proportion of CW gametocytes
at the time of mosquito feeds was fitted as a covariate. Day
nested within mouse was included as a random effect to
adjust for non-independence associated with the contri-
bution of several mosquitoes per feed on an individual
mouse, and with multiple feeds that were performed on
each infection at different days.
3. RESULTS
We carried out four experiments to compare the effects of
drug treatment on the survival and transmission of two
P. chabaudi genotypes (from the same genetic background
and not been previously exposed to drugs) that differ in
virulence. Untreated infections with the virulent genotype
(CWvir) resulted in significantly greater weight loss and
anaemia compared with infections with the avirulent gen-
otype (CWavir; electronic supplementary material, data
S3). Drug treatments in all experiments were given
from day 5 after infection, when symptoms (RBC loss
and weight loss) were first observed, and consisted of
either artemisinin (experiments 1–4) or pyrimethamine
(experiment 4). Both drugs kill asexually replicating para-
sites but artemisinin also kills transmission stages
(gametocytes) [22]. All treatment regimens alleviated
symptoms (anaemia and weight loss) of mice infected
with CWvir to levels observed in untreated CWavir infec-
tions (see the electronic supplementary materials, data
S4). The drugs, doses and numbers of independent infec-
tions for each treatment group, in each experiment, are
given in table 1.
(a) In-host replication
In our first 3 experiments, we tested whether virulence pro-
vides an in-host survival advantage (density of asexually
replicating stages) to parasites exposed to various doses
and durations of artemisinin treatment, in single (exper-
iments 1 and 2) and in the more ecologically realistic
scenario of genetically diverse infections (experiment 3;
table 1).
Infections with CWvir always produced more asexual
parasites than infections with CWavir (F1,103 ¼ 208.4,
p , 0.001). Drug treatment reduced CW parasite loads
(F4,99 ¼ 83.7, p , 0.001) in all treatment groups, but
had disproportionally greater effects on the densities of
CWavir compared with CWvir (genotype by dose inter-
action: F4,93 ¼ 5.2, p , 0.001; figure 1). For example,
50 mg kg21 artemisinin reduced the cumulative (days
6–21) parasite densities of avirulent parasites by fivefold
and that of virulent parasites only by 1.5-fold compared
with placebo infections (20.7 and 20.18 reduction on
a 10log scale, respectively; figure 1). Therefore, CWvir
asexual parasites were less sensitive than CWavir to artemi-
sinin treatment in all dose and duration regimens tested.
This includes: treatment of single-genotype infections for 4
consecutive days (experiment 1), for 1 day (experiment 2),
and when administered for 1 day to parasites competing in
mixed infections (experiment 3). This pattern was
consistent across experiments despite differences in magni-
tude of effects generated by different treatment durations
(for example, a single day treatment eliminated fewer para-
sites compared with giving the same dose for four
consecutive days (F4,89¼ 5.1, p¼ 0.001).
(b) Between-host transmission
In experiment 4, we measured how transmission from
mixed infections (as for experiment 3) is influenced by
virulence and drug treatment using the same artemisinin
regimens as in experiment 3 and pyrimethamine regimens
according to our previous experiments [12]. We exposed
infected mice to mosquitoes on day 7 post infection
(one gametocyte development cycle after drug treatment)
and again on days 11, 15 and 19, to estimate overall
(cumulative) transmission success for parasites in each
treatment group.
4 P. Schneider et al. Chemotherapy and virulence evolution
Proc. R. Soc. B
 on September 28, 2012rspb.royalsocietypublishing.orgDownloaded from 
First, we analysed whether the probability that mosqui-
toes became infected—with parasites of any genotype—
was influenced by the CW genotype and interactions with
drug and dose. We obtained an average of 23.3 per cent
infected mosquitoes per feed, ranging from 0 to 100%
(table 2). However, the proportion of mosquitoes infected
was not significantly influenced by the virulence of the CW
genotype, drug, dose used, or by interactions between
genotype and drug or dose (table 3a).
Second, because malaria parasites reproduce sexually
in the blood meal, infected mosquitoes could harbour
the CW and DK genotypes as a result of selfing, as well
as progeny from recombination between the co-infecting
genotypes. Therefore, we quantified how many CW
andDK alleles were harboured by infectedmosquitoes and
used the proportion ofCWrelative toDK alleles as ametric
to compare the transmission success of CWavir and CWvir.
The representation of CWvir alleles was always greater
than CWavir, and this difference was mediated by drug
treatment (figure 2; with statistical results presented in
table 3b). Treatment of infections with either drug did
not significantly affect the transmission success of CWvir.
In contrast, transmission of CWavir was significantly
reduced when infections were treated with pyrimethamine.
The same pattern was observed with artemisinin, but it was
not significant (table 3b and figure 2). We investigated
whether variation in gametocyte densities could explain
why CWavir, but not CWvir, suffered a reduction in trans-
mission from drug-treated infections. First, in both
treated and untreated infections, for a given gametocyte
density, CWvir achieved a greater representation, relative
to DK, in the gametocyte pool than CWavir (F1,47 ¼
147.77, p, 0.001; figure 3a). Second, the representation
of CW in the gametocyte pool is positively and linearly
correlated with allele frequency in infected mosquitoes
(effect size 1.46+0.20. t ¼ 7.40, p , 0.001; table 3b and
figure 3b). However, the analysis presented in table 3b
controls for variation in the representation of CW in the
gametocyte pool, which suggests that the different effects
of drugs on the transmission of virulent and avirulent
parasites cannot be entirely explained by variation
gametocyte densities.
4. DISCUSSION
Our experiments used two drugs (pyrimethamine and
artemisinin), with each applied across a range of doses
and regimens to avirulent and virulent parasite genotypes
in single- and in mixed-genotype infections. As we found
previously, the virulent parasites were less susceptible to
pyrimethamine [12], and we can now report that is also
true for artemisinin, an antimalarial drug with a different
mode of action, in single and in genetically mixed
infections (figure 1). Treatment with pyrimethamine dis-
proportionately reduced the transmission of avirulent,
compared with virulent, parasites from mixed infections
(figure 2). Thus, pyrimethamine treatment generated
selection which favoured the virulent genotype owing to
its survival and transmission advantage. Under artemisi-
nin treatment, the virulent parasites also experienced a
disproportionate survival advantage but this did not gen-
erate a significant transmission advantage. It may be that
artemisinin can also select for virulent parasites (if
we had insufficient power to detect the transmission
effect observed for pyrimethamine), or it may be that
virulent parasites do not gain a transmission advantage
with artemisinin treatment because this drug kills
both asexual stages and gametocytes (pyrimethamine
kills only asexual stages). However, we note that virulent
parasites did not experience a transmission disadvantage,
so artemisinin did not select against virulent parasites.
Together, our experiments provide proof-of-principle
that virulence can be associated with parasite responses
to drug treatment across a range of treatment regimens.
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Figure 1. Drug sensitivity of virulent and avirulent parasite
genotypes. Virulent (black squares, CWvir) asexual parasites
are less sensitive to artemisinin treatment than avirulent
(grey circles, CWavir) parasites in all dose and duration regi-
mens tested. Infections were treated with placebo (0) or
artemisinin at doses of 50, 100, 150 or 200 mg kg mouse21.
Data presented are model predictions from experiments 1–3
(mean and s.e. of cumulative asexual parasite densities from
day 6–21 after infection) from GLMs controlling for weight
and RBC density at the day of infection and asexual parasite
density at time of treatment. Note that doses 0 (Navir ¼ 14,
Nvir ¼ 14), 50 (Navir ¼ 15, Nvir ¼ 15) and 100 (Navir ¼ 13,
Nvir ¼ 15) were used in all three experiments, but doses
150 (Navir ¼ 5, Nvir ¼ 5) and 200 (Navir ¼ 5, Nvir ¼ 4) were
only used in, respectively, experiments 1 and 2.
Table 2. Probability of mosquito infection. Mean and range
for the percentage of infected mosquitoes throughout
infections for each treatment group in experiment 4. Means
were calculated across days with two feeds per treatment
group done at each of four different days (N ¼ 8), except in
the CWavir PYR 3 and ART 100 treatment groups that each
had one feed excluded from analysis (N ¼ 7). Treatment
groups are: PYR 1: pyrimethamine 1 mg kg–1; PYR 3:
pyrimethamine 3 mg kg21; ART 50: artemisinin
50 mg kg21; ART 100: artemisinin 100 mg kg21.
drug dose CWavir CWvir
placebo 31.4 (0–92) 28.5 (0–100)
PYR 1 39.3 (0–100) 11.5 (0–92)
PYR 3 35.9 (0–92) 36.4 (0–88)
ART 50 24.1 (0–48) 12.2 (0–72)
ART 100 6.2 (0–32) 6.9 (0–36)
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The next step is to examine whether this association holds
across a broader range of drugs and genetic back-
grounds—in which different traits underlie virulence—to
determine whether, in general, more virulent strains are
less susceptible to drug treatment. If they are, the survival
advantage provided by virulence could apply to a variety
of different stressors that inhibit growth (as has been
shown for immunity [39] and competition [40]).
The mechanism by which virulence could reduce sensi-
tivity to drugs in our experiments is unclear. The parasites
used in our experiments had not previously been exposed
to drugs and did not acquire any known classical drug
resistance mutations during the experiments. This means
our results are not confounded by the de novo evolution
of classical drug resistance. Our analyses have controlled
for the number of parasites present at the time of treatment
so it is unlikely that a simple mechanism of ‘safety in num-
bers’ is the sole cause of the virulent parasites’ advantage.
However, our data do show that CWvir parasites recover
faster from drug treatment, which could be because
CWvir has a faster asexual replication rate than CWavir.
Alternatively, dormant stages have been reported in the
human malaria parasite P. falciparum in response to treat-
ment with D-sorbitol, pyrimethamine, mefloquine and
artemisinin-derivatives. These stages survive treatment
and recover asexual replication in a dose-dependent
manner up to 20 days later [9–11,18, 41,42]. Our obser-
vations could be explained if virulent parasites form more
dormant stages, or produce dormant stages that recover
asexual replication more efficiently [43,44]. In response
to our earlier report on virulence-dependent drug sensi-
tivity to pyrimethamine [12], it was suggested that the
effect may be due to overexpression or amplification of
genes in the folate biosynthesis pathway, or by altered pyr-
imethamine transport processes [45]. These potential
classical resistance mechanisms are all specifically linked
to drugs that target the folate biosynthesis pathway and
so are unlikely to explain the virulence-dependent drug
sensitivity to artemisinin reported here.
Table 3. Between-host transmission (experiment 4). (a) Results of MCMCglmm analysis (see the electronic supplementary
materials, data S2) for the proportion of mosquitoes infected. The estimation of effects is presented (posterior mean) with
95% credible intervals (Bayesian confidence interval; CI) on a logit scale. (b) Results of the lme analysis of transmission
success. Estimated effect sizes with standard errors (s.e.) and statistics are presented. For both sections, statistical outcomes,
using CWavir and no drug controls as references, with significant results indicated in bold. As doses within drug type were not
significantly different, results are shown for pyrimethamine- or artemisinin-treated infections compared to no drug treatment
control. Treatment groups and sample sizes (mosquito cages) are: placebo, no drugs (Navir ¼ 8, Nvir ¼ 8); PYR,
pyrimethamine at 1 or 3 mg kg21 (Navir ¼ 15, Nvir ¼ 16); ART, artemisinin at 50 or 100 mg kg21 (Navir ¼ 15, Nvir ¼ 16).
posterior mean CI
(a) proportion of infected mosquitoes
gametocyte density DK þ CW 3.57 2.44; 4.87
genotype (CWvir) 22.10 26.32; 2.34
drug PYR 0.87 22.55; 4.75
ART 1.35 22.27; 5.35
genotype by drug interactions CWvir  PYR 20.54 26.21; 4.69
CWvir  ART 21.10 26.91; 4.16
effect size s.e. t-value p-value
(b) transmission successa of CW genotypes
proportion CW in gametocytes 1.46 0.20 7.40 <0.001
genotype (CWvir) 20.27 0.19 21.43 0.17
drug PYR 20.18 0.13 21.35 0.19
ART 20.01 0.14 20.03 0.97
genotype by drug interactions CWvir  PYR 0.44 0.21 2.10 0.04
CWvir  ART 0.08 0.22 0.38 0.71
aThe proportion of CW alleles within infected mosquitoes (arcsine square root transformed).
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Figure 2. Transmission success in mixed-genotype infections.
In mixed infections with a common competitor (DK),
virulent (CWvir) parasites have a transmission (fitness)
advantage over avirulent (CWavir) parasites, which is
enhanced by treatment with pyrimethamine. Transmission
success is presented as the mean+ s.e. of the proportion of
CW alleles, relative to DK alleles, within infected mosqui-
toes. Treatment groups with sample sizes (number of feeds
resulting in infected mosquitoes for avirulent and virulent
CW genotypes) were: Placebo: no drugs (Navir ¼ 5, Nvir ¼
3); PYR: pyrimethamine at 1 or 3 mg kg21 (Navir ¼ 8,
Nvir ¼ 7); ART: artemisinin at 50 or 100 mg kg21 (Navir ¼
8, Nvir ¼ 8) and feeds were carried out on days 7, 11, 15
and 19 post infection.
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We also found that the virulent genotype achieved
greater representation (relative to a common competitor)
in the pool of transmitting gametocytes (figure 3a) and in
mosquito infections (figures 2 and 3b). Our analyses
suggest that differences in gametocyte production between
CWavir and CWvir are not solely responsible for this effect.
Instead, the loss of infectiousness of CWavir could occur if
its gametocytes are more sensitive to drugs than the
common competitor (DK) and/or if CWvir’s gametocytes
are less sensitive than DK’s. Alternatively, as observed in
the host, CWvir parasites might also replicate faster in the
mosquito and produce sporozoite stages inside oocysts at
a faster rate than DK.
Some field data from human malaria infections are
consistent with our observations that more virulent para-
sites have a survival advantage in drug-treated hosts.
First, it is often assumed that treatment failures are due
to classical resistance mechanisms, but not all parasites
surviving recommended drug treatment have classical
resistance to the antimalarial drug they were exposed to
[9,41,42,46,47], suggesting resistance can be genetically
and phenotypically complex. The molecular mechanisms
involved in artemisinin resistance are apparently not
simple, and mutations related to artemisinin resistance
do not fully account for delayed clearance times, which
may be due to quiescent parasite stages [9–11,32,43,
44]. Second, high parasite densities at the time of treat-
ment increase the likelihood of treatment failure [48].
Third, the evolution of classical resistance has been
linked to increases in cases of severe malaria and case-
fatality rates [49,50]. This could be because treatment
regimens reduce infection prevalence, which lowers
levels of protective immunity, so that infections become
rarer but result in more severe symptoms, or it could be
due to the selection of virulent parasites that also have
classical drug resistance. These possibilities highlight
the need for virulence assays that can be used in natural
systems where there are many circulating parasite
genotypes, different epidemiological settings and a range
of interventions being applied.
If our results apply to infectious diseases in general,
they suggest the following scenario: virulent parasites
are more likely to survive drug treatment. This will
increase the risk of treatment failure and so, higher
doses/durations of drugs may be required for radical
cure. If higher drug doses are provided to control virulent
parasites, then selection for virulence will be maintained.
Parasite virulence may interact with the evolution of clas-
sical drug resistance in multiple, non-exclusive and
potentially contradictory ways [51]: (i) because more
parasites from virulent genotypes survive treatment,
greater numbers provide more opportunities for classical
resistance mutations to arise; (ii) as virulent parasites
are able to tolerate drugs better, then there is stronger
selection for classical resistance to emerge in avirulent
parasites; (iii) following on, if classical resistance
mutations provide a smaller benefit to virulent parasites,
these mutations will spread faster in avirulent popu-
lations; and (iv) because the evolution of classical
resistance is often associated with fitness costs in
untreated infections [52], compensatory mechanisms
may involve the subsequent evolution of traits underpin-
ning virulence. Evaluating the occurrence of these
scenarios in nature, and how this is affected by the
spread of resistance and associated changes of treatment
regimens will require a combination of laboratory exper-
iments and the monitoring of molecular and phenotypic
markers of virulence and resistance in natural infections.
This will not be easy but is especially important for dis-
eases, such as malaria, where virulence, classical drug
resistance, and compensatory mutations involve complex
and interacting phenotypes.
All experiments were carried out in accordance with the UK
Animals Scientific Procedures Act 1986, have been subject to
ethical review and approved by the Home Office, and the
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Figure 3. Correlation between gametocyte density, representation in the gametocyte pool and mosquito infections. The density
of gametocytes (gcts) for avirulent (grey circles, CWavir) and virulent (black circles, CWvir) parasites in mixed genotype infec-
tions with common competitor, DK, correlates positively with representation in the gametocyte pool and in mosquitoes.
(a) For a given gametocyte density, CWvir (r
2 ¼ 0.31, p ¼ 0.02) gains greater representation in the gametocyte pool than
CWavir (r
2 ¼ 0.39, p, 0.001). (b) The proportion of CW gametocytes correlates positively with the frequency of the CW
allele within infected mosquitoes (r2 ¼ 0.85, p , 0.001; for both genotypes). Put simply, because CWvir achieves greater
representation than CWavir in the gametocyte pool, it gains greater representation in infected mosquitoes. Data are presented
for all treatment groups ((a) experiment 4 and experiment 3 on days of mosquito feeds only, Nvir ¼ 127, Navir ¼ 132;
(b) experiment 4 Nvir ¼ 18, Navir ¼ 21).
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